LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) is expected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect LENZ Therapeutics to post earnings of ($0.41) per share for the quarter.
LENZ Therapeutics Price Performance
NASDAQ:LENZ opened at $22.53 on Tuesday. The stock has a 50 day simple moving average of $26.38 and a 200 day simple moving average of $27.00. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $35.40.
About LENZ Therapeutics
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
- Five stocks we like better than LENZ Therapeutics
- Where to Find Earnings Call Transcripts
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
- Retail Stocks Investing, Explained
- 3 Explosive Tech Stocks Breaking Out Right Now
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
